Postdoc - Genetic screens for metabolic vulnerabiities
Your function within the department
The research group of Reuven Agami at the division of Oncogenomics aims at the identification of novel cellular vulnerabilities that can be exploited for cancer therapies. For this purpose, we develop innovative genomic and genetic tools. Key targets and processes are mRNA translation, non-coding RNAs, and enhancers. In particular, we employ novel unbiased functional genetic screening approaches (based on own CRISPR and RNAi tools), perform mechanistic studies to understand their connection with the cancerous phenotype, and use this information for the development of innovative cancer therapeutic approaches.
Three main themes are currently running in the lab:
- We use ribosome sequencing and metabolic parameters to identify tumour-specific amino acid vulnerability (see Loayza-Puch Nature 2016 for more details).
- We perform CRISPR-Cas9 based functional screens to study the role of regulatory DNA elements in cancer (see Korkmaz et al., Nature Biotechnology 2016).
- We study the importance of the epi-transcriptome (RNA modifications) to gene expression, and its influence on cancer progression (see Slobodin B et al., Cell 2017).
We seek to recruit an ambitious postdoc, capable of independent thinking, with a strong commitment to science, and a solid experience in molecular biology. In particular past experience with mRNA translation and metabolic processes in human cancer is essential. General knowledge about functional screening with RNAi and CRISPR tools and epigenetics is an advantage. We expect the candidate to be highly self-motivated, creative, and able to work in a team
Your career opportunities and terms of employment
You will join an international research team in a stimulating and interactive research environment. You will have access to unique data coming from our experiments, and you will have the opportunity to follow high-quality courses offered by the NKI postdoc career development program.
Your temporary employment will be for a period of 4 years. We offer a competitive salary (including possibilities for additional tax-reduction) and housing facilities in the vicinity of the institute. The gross salary per month will be from € 3.421,- to € 3.840,- according to the FWG-function group 55, depending on education and previous experience. The terms of employment will be in accordance with the CAO Ziekenhuizen (Collective Labour Agreement for Hospitals).
For further information please visit our home page (https://www.nki.nl/divisions/oncogenomics/jacobs-j-group/) or contact Prof. Reuven Agami at tel. +31 20 5122079 or e-mail: firstname.lastname@example.org
When applying please include a list of your publications and the contact details of 2 referees.
Loayza-Puch, F., K. Rooijers, L.C. Buil, J. Zijlstra, J.F. Oude Vrielink, R. Lopes, A.P. Ugalde, P. van Breugel, I. Hofland, J. Wesseling, O. van Tellingen, A. Bex, and R. Agami, Tumour-specific proline vulnerability uncovered by differential ribosome codon reading. Nature, 2016. 530(7591): p. 490-4.
Korkmaz, G., R. Lopes, A. P. Ugalde, E. Nevedomskaya, R. Han, K. Myacheva, W. Zwart, R. Elkon and R. Agami (2016). "Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9." Nat Biotechnol 34(2): 192-198.
Slobodin, B., R. Han, V. Calderone, J.A. Vrielink, F. Loayza-Puch, R. Elkon, and R. Agami, Transcription Impacts the Efficiency of mRNA Translation via Co-transcriptional N6-adenosine Methylation. Cell, 2017. 169(2): p. 326-337 e12.